Table 1.
Demographics and baseline characteristics of hospitalized patients with COVID-19.
| Normal weight (n = 473) | Overweight (n = 669) | Obese (n = 492) | p-value | |
|---|---|---|---|---|
| Male sex (%) | 301 (63.6) | 471 (70.4) | 268 (54.5) | <0.001 |
| Age (years) | 72.0 [60.0-79.1] | 67.0 [58.0-77.0] | 63.1 [53.1-74.0] | <0.001 |
| BMI (kg/m2) | 23.2 [21.8-24.2] | 27.3 [26.2- 28.4] | 33.1 [31.2-36.1] | <0.001 |
| Active smoker (%) | 18 (3.8) | 26 (3.9) | 20 (4.1) | 0.977 |
| Alcohol abuse (%) | 10 (2.1) | 24 (3.6) | 8 (1.6) | 0.075 |
| Comorbidities | ||||
| Hypertension (%) | 181 (38.3) | 301 (45.0) | 266 (54.1) | <0.001 |
| Diabetes, with complications (%) | 24 (5.1) | 48 (7.2) | 45 (9.1) | 0.049 |
| Diabetes, without complications (%) | 72 (15.2) | 110 (16.4) | 121 (24.6) | <0.001 |
| Rheumatic disease (%) | 47 (9.9) | 68 (10.2) | 60 (12.2) | 0.441 |
| Auto-immune disease (%) | 36 (7.6) | 45 (6.7) | 37 (7.5) | 0.812 |
| Organ transplant | 13 (2.7) | 8 (1.2) | 4 (0.8) | 0.033 |
| HIV and/or AIDS (%) | 1 (0.2) | 2 (0.3) | 5 (1) | 0.208 |
| Chronic cardiac disease (%) | 158 (33.4) | 206 (30.8) | 140 (28.5) | 0.250 |
| Asthma (%) | 37 (7.8) | 71 (10.6) | 65 (13.2) | 0.025 |
| Other chronicpulmonary disease (%) | 87 (18.4) | 107 (16.0) | 103 (20.9) | 0.097 |
| Chronic kidneydisease (%) | 52 (11.0) | 63 (9.4) | 46 (9.3) | 0.614 |
| Mild liver disease (%) | 12 (2.5) | 13 (1.9) | 21 (4.3) | 0.055 |
| Severe liver disease (%) | 5 (1.1) | 8 (1.2) | 5 (1.0) | 0.953 |
| Chronic neurologicdisease (%) | 72 (15.2) | 76 (11.4) | 53 (10.8) | 0.069 |
| Hematologic disease (%) | 30 (6.3) | 29 (4.3) | 13 (2.6) | 0.020 |
| Dementia (%) | 18 (3.8) | 21 (3.1) | 8 (1.6) | 0.112 |
| Malignancy (%) | 52 (11.0) | 42 (6.3) | 24 (4.9) | 0.001 |
Comparison of demographic and characteristic data between patients with normal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25-29.9 kg/m2) and obesity BMI (≥30 kg/m2). Categorical data are count (%) and compared by χ2 or Fisher’s exact tests. Continuous data are median [IQR] and compared by Kruskal-Wallis test. Definitions of comorbidities are presented in Supplemental Table S1 . An overall p-value <0.05 is considered statically significant. Post-hoc analysis between groups is presented in Supplemental Table S4 .